(OTCBB: OCTL), (OTCBB: PYTO), (OTCBB: FVRG), (OTCBB: CYKN).

RealPennies.com: Turning Pennies into dollars: (OTCBB: OCTL), (OTCBB: PYTO), (OTCBB: FVRG), (OTCBB: CYKN).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://octl.realpennies.com

Earlier today Octillion Corp. (OTCBB: OCTL), an alternative energy technology incubator, is pleased to have provided an update on its ongoing research and development activities for the Company's first-of-its-kind transparent glass window potentially capable of generating electricity.

Octillion's NanoPower Window(TM) technology uses silicon nanoparticles that have the potential to convert conventional home, office and industrial glass windows into those capable of converting solar energy into electricity. The silicon nanoparticles are created through a unique electrochemical and ultrasound process that produces identically sized (1 to 4 nanometers in diameter) highly luminescent nanoparticles of silicon that provide varying wavelengths of photoluminescence with high quantum down-conversion efficiency of short wavelengths (50% to 60%).

"Our silicon nanoparticles are the foundation of our NanoPower Windows," states Mr. Nicholas S. Cucinelli, President and CEO of Octillion Corp. "In fact, independent tests have shown that the same silicon nanoparticles used in Octillion's NanoPower Window(TM) are also able to enhance the power output of conventional solar cells by up to 70% in the ultraviolet light range and 10% in the visible. Consequently, and contingent on the success of our ongoing research, we are optimistic that transparent cells based entirely on our nanomaterials will one day offer a cost-effective photovoltaic enhancement to conventional windows."

In mid-2007, collaborating research scientists successfully engineered and assembled an early lab scale model of Octillion's photovoltaic NanoPower Window(TM), a see-through developmental prototype, which achieved optically active down-conversion and displayed good electrical properties with no electrical shorts. This significant milestone was achieved in part due to the successful development of a protocol for reliably depositing nanoparticles onto glass surfaces using a proprietary electro spray system able to produce nanofilms of controllable thickness.

The electro spray deposition system allows the silicon nanoparticles to retain their high efficiency of down-conversion of UV light to the visible after being sprayed, a procedure that does not compromise the optical characteristics of the nanoparticles, both in intensity and spectral distribution, a prerequisite for efficient photovoltaic conversion.

Since the development of the initial prototype, the Company has been working to establish photovoltaic characteristics in its NanoPower Window(TM). These efforts include experimentation with different types and thicknesses of ultrathin transparent conductive coatings, verification of conversion efficiencies at various wavelengths (UV, blue, green, red, etc.), refinements to our electro spray deposition process, and variation of the deposition thickness of silicon nanoparticles in order to achieve maximum electronic transport and collection efficiency.

Successful outcomes from the above noted experimentation will allow the Company to advance its research and development initiatives for the NanoPower Window(TM). Future research goals will include, among other things, optimizing photovoltaic efficiency versus window transparency and eventually conducting a cost benefit engineering analysis.

Octillion Corp. is a technology incubator focused on the identification, acquisition, development and eventual commercialization of emerging, leading-edge alternative energy technologies.

Through established relationships with universities, research institutions and government agencies, we strive to identify technologies and business opportunities on the leading edge of innovation that have the potential of serving significant and unmet market needs.

Once a technology has been identified, we fund the research and development activities relating to the technology with the intention of ultimately, if warranted, licensing, commercializing and marketing the subject technology, either through internal resources, collaborative agreements or otherwise.

For more info: http://pyto.realpennies.com

PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB:ET6), announced earlier today that research outcomes from ongoing in vitro studies of the Company's sponsored anti-cancer compounds have successfully demonstrated the ability to kill a strain of human brain cancer cells which is otherwise highly-resistant to currently available drugs.

Led by Dartmouth College researcher Dr. Gordon Gribble, researchers have determined that, one of several patented "bis-intercalator" anti-cancer compounds being developed by PhytoMedical has achieved a 50% or greater cancer cell kill rate at a minimum concentration in studies of the SF-295 strain of human glioblastoma (brain) cancer cells -- a significant outcome, given these brain cancer cells' drug-resistant nature.

"The outstanding results of this human cancer cell study is an extremely important step towards finding a potential solution for treating glioblastoma, an often fatal form of cancer," commented Greg Wujek, President, CEO of PhytoMedical Technologies, Inc. "The demonstrated cytotoxic effects of this unique patented compound on such a resistant strain of cancer has given us the confidence to move forward in our research and improve upon the concept of bis-intercalation and the promise it holds for the control of cancer."

In important in vitro experiments, researchers tested several variations of patented bis-intercalator compounds. These compounds have the unique capability to "intercalate" or insert their anti-cancer molecules inside DNA sites of specific cancer cells, thereby preventing the ability of the cancer cells to replicate and ultimately forcing their death.

Among several compounds tested in vitro against an often fatal strain of human glioblastoma (brain) cells, researchers have identified a high performance compound which requires the least concentration in order to achieve a 50% or greater cancer cell kill rate. This strong activity against glioblastoma cancer cells is a significant achievement given these cells' strong resistance to currently available anticancer drugs such as Lomustine, Carmustine, Nitrosourea, Hydroxyurea, and Procarbazine.

PhytoMedical's Cancer Research: Killing Cancer's DNA

PhytoMedical is developing a novel class of patented anti-cancer agents that have a cytotoxic' or poisonous affinity for cancer cells and are designed to bind more tightly to cancer cell DNA than many conventional anticancer drugs by a process called bis-intercalation or "double binding," much like a molecular staple. Because the DNA is the blueprint of life for the cancer cell, such binding stops the replication of the DNA, which prevents the growth of the cancer cell and it dies.

DNA is present in the nucleus of every cell of all living organisms, which are constantly dividing through a process in which the DNA in the nucleus of the original cell replicates itself to be present in the nuclei of the two new ("daughter") cells. If this replication cannot occur, the cell will die and the organism will eventually stop growing and die. Cancer is characterized by the development of abnormal cells that divide uncontrollably and have the ability to infiltrate and destroy normal body tissue.

At present, anticancer molecules designed to block the replication of DNA do so through "intercalation," a mechanism in which the drug inserts itself between one set of adjacent base pairs of the DNA. PhytoMedical believes a more effective anticancer strategy is to design molecules ("bis-intercalators") that can intercalate simultaneously at two DNA sites, thus further increasing the binding between the drug and the DNA of specific cancer cells in order to stop their replication and ultimately resulting in the death of the cancer cell.

For more info: http://fvrg.realpennies.com

ForeverGreen Worldwide Corporation, (OTCBB: FVRG) a manufacturer and distributor of all natural whole foods, announced earlier today that the company has entered the energy drink market with the introduction of AmpliFire, an all-natural energy drink.

The energy drink market, led by Red Bull , is estimated to grow 12% annually and exceed $39 billion US dollars by 2010 according to market research publicist Global Industry Analysts.

ForeverGreen's new AmpliFire takes an all-natural approach to boosting energy without artificial sugars or synthetic caffeine. Packaged in a convenient 2-ounce bottle, AmpliFire includes a blend of natural, safe, clean and organic ingredients for instant energy that lasts for hours without the "crash" common to many products currently on the market.

AmpliFire utilizes ForeverGreen's patent-pending AMP technology to take natural plant concentrates and render them water-soluble, making whole-plant benefits instantly available to the body. This exclusive technology combined with AmpliFire's exotic, full-flavored ingredients arouses the senses immediately.

ForeverGreen Worldwide Corporation develops, manufactures and distributes an expansive line of all natural products to North America, Australia, Europe, and Asia. Offerings include FrequenSea a whole-food beverage, 24 Karat Chocolate , ForeverYoung Essential Oils, Pulse, a whole-food snack or meal replacement and an entire catalog of meals, snacks, household cleaners and personal care products.

For more info: http://cykn.realpennies.com

Cyberkinetics Neurotechnology Systems, Inc. (OTCBB: CYKN; "Cyberkinetics") announced earlier today that Timothy R. Surgenor, Cyberkinetics' President and Chief Executive Officer, will present at the First Annual OneMedPlace (OMP) Finance Forum at 2:40 p.m. (PST) on Monday, January 7, 2008, at the Sir Francis Drake Hotel in San Francisco, California.

In his presentation, Mr. Surgenor will provide an update on Cyberkinetics' strategy to develop the Andara OFS (Oscillating Field Stimulator) Therapy, which is designed to stimulate nerve growth and restore function following a nervous system injury. If the Company's Humanitarian Device Exemption is approved by the Food and Drug Administration, the Andara OFS System could be the first commercially available neurotechnology device designed to partially restore sensation and motor function in acute spinal cord injuries.

Cyberkinetics Neurotechnology Systems, Inc., a leader in the neurotechnology industry, is developing neural stimulation, sensing and processing technology to improve the lives of those with severe paralysis resulting from spinal cord injuries, neurological disorders and other conditions of the nervous system. Cyberkinetics' product development pipeline includes: Andara OFS Therapy for acute spinal cord injury, an investigative device designed to stimulate nerve repair and restore sensation and motor function; the BrainGate System, an investigative device designed to provide communication and control of a computer, assistive devices, and, ultimately, limb movement; and a pilot program in the detection and prediction of seizures due to epilepsy.

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com